Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
16/06/26	0.4780 kr	+0.74%	584,054
15/06/26	0.4745 kr	-2.37%	481,193
12/06/26	0.4860 kr	+6.23%	681,022
11/06/26	0.4575 kr	+3.62%	592,487
10/06/26	0.4415 kr	-3.92%	1,521,143

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Delayed Nasdaq Stockholm Other stock markets 15:23:36 16/06/2026 +03			5-day change	1st Jan Change
0.4780 ^SEK	+0.74%		+4.03%	-42.34%

06-12	Alzinova raises SEK15.3m from warrants: underwriting not required	FW
06-08	Alzinova raises SEK 15.2 million before issuance costs	FW

Market Cap	73.53M 7.84M 6.76M 6.22M 5.83M 10.96M 741M 11.07M 28.72M 363M 29.42M 28.8M 1.26B	P/E Ratio 2026 *	-1.48x	P/E Ratio 2027 *	-0.97x
Enterprise Value	70.53M 7.52M 6.48M 5.97M 5.6M 10.51M 711M 10.62M 27.55M 348M 28.22M 27.63M 1.2B	EV / Sales 2026 *	2.25x	EV / Sales 2027 *	-
Free-Float	82.23%	Yield 2026 *	-	Yield 2027 *	-

06-12	Alzinova raises SEK15.3m from warrants: underwriting not required	FW
06-08	Alzinova raises SEK 15.2 million before issuance costs	FW
05-26	Calendar Tuesday May 26	FW
05-25	Calendar Tuesday May 26	FW
05-21	Alzinova secures 80 percent of TO4 warrants	FW
05-20	Alzinova phase 1b results published in scientific journal	FW
05-20	Alzinova AB Publishes Clinical Results with ALZ-101 in Alzheimer?s Research & Therapy	CI
05-13	Alzinova AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-13	Alzinova Q1 loss after financial items SEK 6 mln	RE
05-13	Alzinova reports narrowed operating loss - CEO: we see rapidly growing commercial interest in diagnostics	FW
05-11	Alzinova article on Alzheimer's vaccine published in scientific journal	FW
05-11	Alzinova AB Announces Clinical Results with Alz-101 to Be Published in Scientific Journal	CI
05-05	Eight stocks hit new 52-week lows on the Stockholm Stock Exchange so far today	FW

04-08	RX Securities sees potential upside for Alzinova from Alzheimer's diagnostic collaboration	FW
03-26	DNB Carnegie sees reduced financing risk for Alzinova, but partnership remains critical	FW
06/10/25	Alzinova gets fast track designation from US FDA	RE
06/10/25	Alzinova's Alzheimer's Disease Vaccine Candidate Gets Fast-track Designation from US FDA	MT
04/10/25	Alzinova AB Receives Fast Track Designation from US FDA for ALZ-101 in Alzheimer's Disease	CI

Alzinova AB Stock

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation: Alzinova AB

Chart: Alzinova AB

Latest news : Alzinova AB

Analysts' recommendations: Alzinova AB

Press Releases: Alzinova AB

Quotes and Performance

Course Extremes

Managers and Directors: Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

06-12	Warrants of series TO4 were exercised to approximately 94.2 percent and the Company will receive approximately 15.3 million	AQ
06-08	Alzinova announces preliminary outcome of the exercise of warrants of series TO4	AQ
06-03	The last day of trading with the warrants of series TO4 in Alzinova is today, June 3, 2026	AQ
05-26	Bulletin from the Annual General Meeting of Alzinova AB (publ)	AQ
05-25	The subscription price for warrants of series TO4 in Alzinova has been determined to SEK 0.32 and the exercise period begins today	AQ

1 day	+0.74%
1 week	+4.03%
Current month	+11.03%
1 month	+8.76%
3 months	-29.19%
6 months	-69.59%
Current year	-42.34%

1 week	0.44	0.5
1 month	0.41	0.58
Current year	0.38	0.97
1 year	0.38	2.28
3 years	0.38	4.62
5 years	0.38	9.18
10 years	0.38	44.9

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	01/10/2024
Anders Sandberg COO	Chief Operating Officer	54	17/08/2011
Erik Kullgren DFI	Director of Finance/CFO	57	27/03/2024

Director	Title	Age	Since
Clas Malmeström BRD	Director/Board Member	61	01/09/2015
Anders Waas BRD	Director/Board Member	69	01/01/2018
Carol Routledge BRD	Director/Board Member	-	01/01/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	+0.74%	+4.03%	-71.88%	-84.17%	7.84M
LONZA GROUP AG	+0.94%	+0.95%	-11.82%	-11.91%	43.58B
REVOLUTION MEDICINES, INC.	+4.02%	+7.79%	+294.33%	+536.67%	34.03B
IQVIA HOLDINGS INC.	-1.69%	-2.89%	+13.70%	-17.71%	29.77B
BEONE MEDICINES AG	+1.41%	-0.96%	-0.53%	+33.41%	29.82B
CELLTRION, INC.	+1.16%	+9.79%	+14.27%	+22.28%	25.42B
ASCENDIS PHARMA A/S	+2.40%	+8.49%	-	-	13.87B
MEDPACE HOLDINGS, INC.	+0.03%	+2.10%	+56.75%	+111.91%	13.35B
EUROFINS SCIENTIFIC SE	-0.69%	-3.14%	+2.78%	+2.34%	12.85B
IONIS PHARMACEUTICALS, INC.	+0.93%	+0.57%	+107.81%	+77.40%	12.22B
Average	+0.93%	+2.00%	+45.05%	+74.47%	21.49B
Weighted average by Cap.	+1.10%	+1.86%	+61.51%	+105.68%

	2026 *	2027 *
Net sales	31.35M 3.34M 2.88M 2.65M 2.49M 4.67M 316M 4.72M 12.25M 155M 12.55M 12.28M 535M	-
Net income	-3.2M -341K -294K -271K -254K -477K -32.25M -482K -1.25M -15.79M -1.28M -1.25M -54.65M	-50.35M -5.37M -4.63M -4.26M -4M -7.51M -507M -7.58M -19.67M -248M -20.15M -19.72M -860M
Net Debt	-3M -320K -276K -254K -238K -447K -30.23M -452K -1.17M -14.81M -1.2M -1.18M -51.23M	-7M -746K -643K -592K -555K -1.04M -70.55M -1.05M -2.73M -34.55M -2.8M -2.74M -120M